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Abstract
Hospital systems increasingly utilize pharmacogenomic testing to inform clinical prescribing. 
Successful implementation efforts have been modeled at many academic centers. In contrast, this 
report provides insights into the formation of a pharmacogenomics consultation service at a safety-
net hospital, which predominantly serves low-income, uninsured, and vulnerable populations. The 
report describes the INdiana GENomics Implementation: an Opportunity for the UnderServed 
(INGENIOUS) trial and addresses concerns of adjudication, credentialing, and funding.
THE INGENIOUS TRIAL
Pharmacogenomic-guided therapy has been successfully implemented at several academic 
medical centers.1–3 However, a different model may be required to deliver clinical support to 
providers (physicians, advanced practice nurses, and pharmacists) outside of academic 
centers.
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School of Medicine (IUSM), functions as the home for implementation of genotype-guided 
prescribing in Indiana. IIPM established a Clinical Laboratory Improvement Amendments 
(CLIA)-approved laboratory that utilizes a custom polymerase chain reaction (PCR)-based 
OpenArray genotyping platform to assess 43 germline variants in 14 genes known to affect 
28 medications. The laboratory provides genotyping services for all IUSM-related 
initiatives.
In March 2015, the INGENIOUS trial (NCT02297126) began recruitment within the 
Eskenazi Health System, Indianapolis’ safety-net hospital system servicing predominantly 
low-income and uninsured patients.5 The trial tests whether pharmaco-genotyping impacts 
annual healthcare costs and adverse event incidence. The hospital’s 10 clinics maintain 
common electronic medical record systems (EMR). When any Eskenazi physician enters a 
new prescription for one of 28 drugs, an EMR interruptive alert prompts the prescriber to 
request enrollment in the INGENIOUS trial. With prescriber approval, a patient is 
randomized to receive pharmaco-genotyping or standard care (no pharmaco-genotyping). 
For patients in the genotyping arm, the EMR notifies a research coordinator who approaches 
patients to obtain consent and DNA from agreeing patients.
Within 7 days of sample submission, genotype reports are delivered to the enrolling 
prescriber and uploaded as searchable documents in the EMR. Reports contain 
recommendations for selecting alternative agents or dosing of the medication that triggered 
enrollment, following guidelines from the Clinical Pharma-cogenetics Implementation 
Consortium (CPIC). Supplemental Document 1 contains an example report. Future e-
prescribing of any of the 28 drugs leads to an interruptive automated alert that notifies 
clinicians a genotype report is available and provides dosing recommendations (trial details 
are available in Supplemental Document 2).
ADJUDICATION IN THE INGENIOUS TRIAL
The INGENIOUS trial maintains an adjudication committee that reviews genotypes and 
medication lists for enrollees to ensure clinicians receive actionable results and to protect 
against liability associated with incidental findings. This committee includes a physician, a 
co-investigator of the INGENIOUS trial, and a clinical pharmacology fellow. If the enrolling 
prescriber is no longer involved with a patient’s care when the genotyping results are 
reported, the adjudication committee identifies the most appropriate provider and relays 
actionable results. For example, an enrolling hospitalist may no longer treat a patient after 
discharge and results would be relayed to the primary care physician (PCP) instead. If a PCP 
cannot be identified, a specialist providing longitudinal care or the prescribing physician is 
contacted.
The adjudication committee also alerts the appropriate physician of incidental findings. For 
example, a patient genotyped for a new prescription may have actionable results relevant to a 
second existing prescription. The committee alerts the appropriate provider of these 
incidental findings. Results that do not impact currently prescribed medications are uploaded 
to the EMR’s problem list and will prompt future alerts, but providers are not contacted 
directly in these scenarios. The committee requires ~15 minutes to evaluate a single patient’s 
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genotype in the context of the medication list. To summarize, the following support is 
provided by the INGENIOUS trial: (1) enrolling prescribers are directly sent genotyping 
reports; (2) all Eskenazi prescribers may access the genotype report in the EMR, view 
abnormal genotypes in the problem list, and receive automated interruptive alerts for future 
prescriptions; (3) for actionable results, the adjudication committee contacts appropriate 
physicians. In addition to this process, some clinicians request additional support in applying 
pharmacogenomic data to their patients.
CONSULTATION SUPPORT FOR THE INGENIOUS TRIAL
The strongest impetus for establishing a pharmacogenomics consult service was to support 
the INGENIOUS trial. Figure 1 summarizes the progression of patients from enrollment to 
adjudication to potential consultation. Six physicians, all American Board of Clinical 
Pharmacology (ABCP) board-certified or eligible (Supplemental Table 1), obtained 
privileges to interpret pharmacogenomic testing, staff clinics, and provide inpatient and 
outpatient consults. Eskenazi had no established guidelines for clinical pharmacology 
privileges and a new set of requirements was submitted and accepted by hospital leadership 
(Supplemental Table 2), which included completion of an ABCP-accredited fellowship.
Consults are requested by Eskenazi providers. Genotyping reports include a common phone/
pager number to request pharmacogenomics consults. Outpatient clinic slots were obtained 
at Eskenazi hospital in existing subspecialty clinics to provide patient counseling should 
physicians request this service. Traditional inpatient consultations are available; however, 
due to the time required to report a genotype in the EMR, inpatient consults may lose 
relevance except in emergent cases and prolonged hospital stays.
The consultants principally provide support for Eskenazi clinicians outside of a traditional 
clinic or hospital, in a role analogous to that of a pathologist. In this role, the consultant 
enters a clinical pathology consult (CPC) into the EMR, without performing a history and 
physical. The pharmacogenomics consult service interprets the genotype report in the 
clinical context, analogous to a pathologist reporting a biopsy result. These clinical 
pathology consults (CPT 80500 or 80502) allow the fiexibility to scale the workload to 
demands. In contrast to scheduling an outpatient consultation, the requesting provider, 
patient, and pharmacogenomics consultant achieve their respective goals more efficiently. 
The requesting provider obtains documentation from a consultant validating her or his 
clinical management; the patient achieves the proper dose or alternate medication 
expeditiously; and the consultant can staff these consults around his or her other clinical and 
research duties. No defined documentation is required for an 80500 or 80502 consultation 
(Supplemental Document 3 provides an example). Consults stemming from the initial 
genotyping are offered without charge given the socioeconomic status of this patient 
population. Written notes are placed in the EMR within 24 hours of the consult request.
As education is a core mission of the division, six fellows from our clinical pharmacology 
program rotate on service. These consults provide excellent clinical applications for fellows 
and increase awareness of clinical pharmacology across different medical specialties.
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To date, consult volume has proved modest (Table 1). The INGENIOUS trial is the only 
source of consults at Eskenazi. The physician accrual rate for patient enrollment exceeds 
80%, and 58% of patients approached consent to enroll in the study. To date, 106 patients 
are enrolled in the genotyping arm. Across the Eskenazi health system, the mean combined 
number of “new” prescriptions for all of the 28 drugs is 375 per month. The key enrollment 
challenge is the ability of research assistants to make contact with patients before their 
discharge from the hospital or clinic. To improve enrollment, saliva was added an alternative 
to blood and missed patients are now compensated for travel back to the hospital for study 
enrollment.
Among the 106 patients, 25 actionable genotypes have been reported and 10 consults have 
been requested by Eskenazi physicians. Providers have requested consults for 9% of all 
genotyped patients and 40% of patients with actionable genotypes. While this represents low 
utilization of the consult service, a flexible approach is required to prepare for potential 
spikes in workload when the INGENIOUS trial reaches its monthly target enrollment of 80 
patients. At target enrollment, we predict the pharmacogenomics consult service will require 
3–4% relative value unit-based effort of a full-time equivalent physician (calculations in 
Supplemental Document 4). Actual time required may exceed this effort.
A UNIQUE MODEL
Academic centers have modeled both physician and pharmacistled pharmacogenomics 
consult services. Five unique features of the INGENIOUS trial precipitated development of 
a new model: (1) the implementation occurs in a safety-net hospital system with low-income 
patients and community providers; (2) the genotypes associated with 28 medications are 
available to the entirety of the hospital system; (3) the patients’ genotypes and automated 
EMR support will persist after the trial ends; (4) the consult volume is low and 
unpredictable; and (5) consultation support is not funded by the trial, Eskenazi health 
system, or IUSM. Resultant from these features, we felt it necessary to ensure an additional 
layer of support, beyond the INGENIOUS trial’s adjudication committee. Our consult 
service was built as a flexible model with the ability to adapt to workload changes by 
staffing consults remotely. The service offers a sustainable mechanism for clinical questions 
after the conclusion of the trial.
The model affords framework to build toward future implementation efforts across Indiana. 
The IUSM is affiliated with 19 hospitals and 67 clinics across the state of Indiana. The IIPM 
was tasked by the university to create a pharmacogenomics consult framework capable of 
servicing satellite centers should broad-based genotyping be extended throughout the state. 
With the exception of the EMR support, parallel infrastructure to that described above has 
been established in the Indiana University Health system. The CPC provides a tool to 
support clinicians at satellite hospitals across Indiana, when patients cannot travel to 
Indianapolis.
In contrast to our system, other models employ pharmacists as the primary consultants.2 The 
use of CPCs presently limits our service to physician consultants, as pharmacists are not 
recognized Medicare Part B providers of CPCs. Ultimately, we predict a transition toward 
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greater pharmacist engagement. As providers become familiar with pharmacogenomics, 
most questions will be fielded by knowledgeable pharmacists. With this expectation, the role 
of the physician clinical pharmacologist may be relegated to complicated or unusual cases. 
However, given the circumstances outlined above, the pharmacogenomics consultation 
service is vital during this transitional time. Our model should provide an adaptable solution 
for health systems to meet unpredictable clinical pharmacology demands.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
The interface between the INGENIOUS trial and the pharmacogenomics consult service. 
Any Eskenazi prescriber may enroll her or his patient following an incident new prescription 
of one of the 28 drugs. Patients are randomized to the standard care control arm (no 
genotyping) or the intervention arm (genotyping). Patients randomized to the genotyping 
arm are consented for enrollment by a research assistant, and DNA is collected. The 
genotyping core laboratory provides all pharmacogenomic results and recommendations to 
the EMR, enrolling physician, and the adjudication committee. The adjudication committee 
reviews the genotype for incidental findings and notifies an appropriate physician of 
actionable genotypes. Eskenazi prescribers may choose to follow recommendations or not. 
They may also choose to request a consult if they require additional information or support. 
Consults are derived from provider referrals.
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Table 1
INGENIOUS enrollment and consultation data
Statistic
Value prior
to 7/31/15
Value 8/1/15
to 11/30/15 Total
Months enrollinga 4 4 8
Total alerts to
Eskenazi prescribers
prompted by new
prescriptions
1402 1269 2671
Clinicians clicking
“Yes” to enrollb
539 (38%) 1040 (79%) 1579 (59%)
Patients refusing
enrollment
21 56 77
Patients enrolled in
the control armc
354 252 606
Patients enrolled in the
intervention armd
28 78 106
Actionable genotypese 7 (25%) 18 (23%) 25 (24%)
Consults requested 5 (18%) 5 (6%) 10 (9%)
a
Enrollment began March 20, 2015, although the first intervention arm patient was enrolled in May 2015.
b
The default selection marked on the physician’s alert was “no to enrollment” prior to 7/31/15 and “yes to enrollment” after 8/1/15.
cNo consent is required to enroll in the control arm. The randomization process is designed to place patients 2:1 in the control to pharmaco-
genotyping intervention arms. The process is iterative; when the ratio of patients accrued is greater than 2:1, the randomization algorithm shifts to a 
lower ratio, to drive the balance back toward 2:1 to the extent possible.
dConsent is required to enroll patients in the pharmaco-genotyping intervention arm. To improve enrollment since 12/1/15, saliva was added as an 
alternative to blood and missed patients are now compensated for returning to the hospital to enroll in the study.
eAn actionable genotype is defined as any mutation that affects the dose or drug choice for any currently prescribed medications. This includes 
significant incidental findings. All genotype findings deemed actionable by the adjudication committee are relayed to an appropriate Eskenazi 
provider.
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